Bioniche Life Sciences Inc., a research-based, animal health biopharmaceutical company, has been issued a new patent by the United States Patent and Trademark Office (USPTO) on its core mycobacterial cell wall technology.

The new patent relates to the Company's proprietary composition, Mycobacterial Cell Wall-DNA Complex (MCC), which has been shown to possess immunomodulatory, vaccine adjuvant, and chemotherapeutic activities.

The new patent is: "Method for the treatment of inflammation" (US 6,890,911), inventors Nigel C. Phillips and Mario C. Filion.
"This patent provides protection for the use of mycobacterial cell wall-DNA complexes as anti-inflammatory agents," noted Dr. Nigel C. Phillips, Chief Scientific Officer at Bioniche Life Sciences Inc. and patent co-inventor. "The application fields for this aspect of our core mycobacterial cell wall technology are the treatment of inflammation in general, as well specific uses in immune-mediated inflammation, osteoarthritis, rheumatoid arthritis, glomerulonephritis, colitis, and cystitis. This technology platform already comprises the use of mycobacterial cell wall-DNA complexes as immunomodulators, vaccine adjuvants, anticancer therapeutic agents, and complements other technology platforms within the Company that are either commercialized or under development," he added.

Bioniche's core mycobacterial cell wall technology platform comprises compositions with antiviral, immune adjuvant, immune stimulatory, and anti-inflammatory activity, as well as chemotherapeutic activity against cancer cells.